id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-N-0045-0033,FDA,FDA-2008-N-0045,Letter from Arizona Heart Institute to FDA CBER,Other,Letter(s),2015-09-23T04:00:00Z,2015,9,2015-09-23T04:00:00Z,,2025-06-03T16:15:00Z,,0,0,0900006481c8e6bf
FDA-2008-N-0045-0031,FDA,FDA-2008-N-0045,Email Comment from Panacea Biotec Ltd,Other,Request,2015-09-23T04:00:00Z,2015,9,2015-09-23T04:00:00Z,,2025-06-03T16:13:46Z,,0,0,0900006481c8e6bd
FDA-2008-N-0045-0026,FDA,FDA-2008-N-0045,Regulatory Site Visit Training Program,Notice,Notice of Availability,2015-09-23T04:00:00Z,2015,9,2015-09-23T04:00:00Z,2004-10-26T03:59:59Z,2015-09-25T14:20:20Z,,0,0,0900006481c8df8b
FDA-2008-N-0045-0029,FDA,FDA-2008-N-0045,Letter from Life South to FDA CBER,Other,Letter(s),2015-09-23T04:00:00Z,2015,9,2015-09-23T04:00:00Z,,2015-09-23T14:18:37Z,,0,0,0900006481c8e65b
FDA-2008-N-0045-0048,FDA,FDA-2008-N-0045,Regulatory Site Visit Training Program: Request for Participation,Notice,Notice of Availability,2015-09-23T04:00:00Z,2015,9,2006-04-11T04:00:00Z,2006-05-12T03:59:59Z,2025-06-03T16:19:48Z,E6-5221,0,0,0900006481c8e6cf
FDA-2008-N-0045-0027,FDA,FDA-2008-N-0045,Request for Participation from Aseptic Technologies,Other,Request,2015-09-23T04:00:00Z,2015,9,2015-09-23T04:00:00Z,,2015-09-23T14:09:44Z,,0,0,0900006481c8e659
FDA-2008-N-0045-0032,FDA,FDA-2008-N-0045,"Letter from Merck & Co, Inc to FDA DDM",Other,Letter(s),2015-09-23T00:00:00Z,2015,9,,,2025-04-29T19:03:19Z,,0,0,0900006481c8e6be
FDA-2008-N-0045-0028,FDA,FDA-2008-N-0045,Email Comment from Midwest Eye-Banks,Other,Request,2015-09-23T00:00:00Z,2015,9,2015-09-23T00:00:00Z,,2025-04-29T18:14:09Z,,0,0,0900006481c8e65a
FDA-2008-N-0045-0058,FDA,FDA-2008-N-0045,Letter from National Institutes of Health to FDA DDM,Other,Letter(s),2015-09-23T00:00:00Z,2015,9,,,2025-04-29T20:18:23Z,,0,0,0900006481c8e6d9
FDA-2008-N-0045-0056,FDA,FDA-2008-N-0045,"Letter from SAIC-Frederick, Inc. to FDA DDM",Other,Letter(s),2015-09-23T00:00:00Z,2015,9,,,2025-04-29T19:44:38Z,,0,0,0900006481c8e6d7
FDA-2008-N-0045-0050,FDA,FDA-2008-N-0045,Letter from Gambro BCT to FDA DDM,Other,Letter(s),2015-09-23T00:00:00Z,2015,9,,,2025-04-29T19:37:45Z,,0,0,0900006481c8e6d1
FDA-2008-N-0045-0057,FDA,FDA-2008-N-0045,Regulatory Site Visit Training Program; Correction,Notice,Correction,2015-09-23T00:00:00Z,2015,9,,,2025-04-29T19:54:49Z,E6-6120,0,0,0900006481c8e6d8
FDA-2008-N-0045-0015,FDA,FDA-2008-N-0045,"Regulatory Site Visit Training Program; February 9, 2010",Notice,N-Notice,2010-02-09T05:00:00Z,2010,2,2010-02-09T05:00:00Z,2010-03-12T04:59:59Z,2010-03-26T22:44:45Z,2010-02758,0,0,0900006480a8ffff
FDA-2008-N-0045-0008,FDA,FDA-2008-N-0045,"Regulatory Site Visit Training Program; December 24, 2008",Notice,N-Notice,2008-12-24T05:00:00Z,2008,12,2008-12-24T05:00:00Z,2009-01-24T04:59:59Z,2010-03-26T22:43:43Z,E8-30659,0,0,09000064807f8e05
FDA-2008-N-0045-0001,FDA,FDA-2008-N-0045,"Regulatory Site Visit Training Program; January 22, 2008",Notice,Notice of Availability,2008-01-22T05:00:00Z,2008,1,2008-01-22T05:00:00Z,2008-02-22T04:59:59Z,2015-09-23T13:43:09Z,E8-01006,0,0,090000648039fa61